Codagenix, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-08-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.codagenix.com
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
Phase 1
Withdrawn
- Conditions
- Neoplasm MetastasisBreast Neoplasms
- Interventions
- Biological: CodaLytic
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Codagenix, Inc
- Registration Number
- NCT05600582
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19
Phase 1
Completed
- Conditions
- COVID-19SARS-CoV-2
- Interventions
- Biological: COVI-VAC
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Codagenix, Inc
- Target Recruit Count
- 20
- Registration Number
- NCT05233826
- Locations
- 🇬🇧
HMR, London, United Kingdom
Intramuscular CodaVax-H1N1 in Healthy Adults
Phase 1
Completed
- Conditions
- Influenza, Human
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Codagenix, Inc
- Target Recruit Count
- 69
- Registration Number
- NCT05223179
- Locations
- 🇦🇺
Lis Gilmour, Senior Project Manager, Morayfield, Queensland, Australia
Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
Phase 1
Active, not recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: Normal Saline
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Codagenix, Inc
- Target Recruit Count
- 51
- Registration Number
- NCT04919109
- Locations
- 🇺🇸
Velocity, West Jordan, Utah, United States
🇿🇦University of Witwatersrand (WITS)/Vaccines and Infectious Diseases Analytics (VIDA), Johannesburg, South Africa
Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: COVI-VACOther: Placebo
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Codagenix, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT04619628
- Locations
- 🇬🇧
hVIVO, London, United Kingdom
Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: CodaVax-RSVBiological: Normal saline
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Codagenix, Inc
- Target Recruit Count
- 36
- Registration Number
- NCT04295070
- Locations
- 🇦🇺
Nucleus Network/Q-Pharm, Brisbane, Queensland, Australia
Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Biological: CodaVax-H1N1 influenza vaccineBiological: Normal Saline Placebo
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Codagenix, Inc
- Target Recruit Count
- 33
- Registration Number
- NCT04146623
- Locations
- 🇦🇺
Q-Pharm Pty Limited, Brisbane, Queensland, Australia
Safety Study of Live Attenuated Influenza Vaccine, CodaVax
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Biological: CodaVax-H1N1Biological: Fluzone quadrivalent
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Codagenix, Inc
- Target Recruit Count
- 125
- Registration Number
- NCT03926416
- Locations
- 🇦🇺
Q-Pharm, Herston, Queensland, Australia